Authors: Li-sheng Zheng, Fang Wang, Yu-hong Li, Xu Zhang, Li-ming Chen, Yong-ju Liang, Chun-ling Dai, Yan-yan Yan, Li-yang Tao, Yan-jun Mi, An-kui Yang, Kenneth Kin Wah To, Li-wu Fu
DOI: 10.1371/journal.pone.0005172
Abstract Summary
Vandetanib, an oral cancer drug, can overcome multidrug resistance by blocking ABCC1 and ABCG2 transporters without being affected by them. At non-toxic doses, it significantly enhances chemotherapy effectiveness in resistant cancer cells by increasing intracellular drug accumulation, independent of AKT/ERK signaling pathways.
Why Brain? ðŸ§
Vandetanib reverses cancer drug resistance by blocking ABCC1 and ABCG2 transporters that pump chemotherapy out of cells, potentially improving treatment outcomes when combined with standard drugs.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
